Mehrdad Hefazi (Mehrdad Hefazi Torghabeh)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Topics

Extracorporeal Membrane Oxygenation

Acute Lymphoblastic Leukemia

Epidermal Growth Factor Receptor

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

American journal of hematology

Bone marrow transplantation

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Hemang Yadav, Svetlana Herasevich, Zhenmei Zhang, Bradley A White, Mehrdad Hefazi, William Joseph Hogan, Philip J Schulte, Alexander S Niven, Ognjen Gajic
Pulmonary function as a continuum of risk: critical care utilization and survival after allogeneic hematopoietic stem cell transplantation - a multicenter cohort study. Bone marrow transplantation (2024)
Hemang Yadav, Svetlana Herasevich, Zhenmei Zhang, Bradley A White, Mehrdad Hefazi, William Joseph Hogan, Philip J Schulte, Alexander S Niven, Ognjen Gajic
Pulmonary function as a continuum of risk: critical care utilization and survival after allogeneic hematopoietic stem cell transplantation - a multicenter cohort study. Bone marrow transplantation 59 (7) (2024)
Hemang Yadav, Svetlana Herasevich, Zhenmei Zhang, Bradley A White, Mehrdad Hefazi, William Joseph Hogan, Philip J Schulte, Alexander S Niven, Ognjen Gajic
Pulmonary function as a continuum of risk: critical care utilization and survival after allogeneic hematopoietic stem cell transplantation - a multicenter cohort study. Bone marrow transplantation 59 (7) (2024)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology 99 (2) (2023)
Naseema Gangat, Omer S Karrar, Moazah Iftikhar, McCullough Kristen, Isla M Johnson, Maymona Abdelmagid, Mostafa Abdallah, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. American journal of hematology (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology 99 (2) (2023)
R Leo Sakemura, Mehrdad Hefazi, Michelle J Cox, Elizabeth L Siegler, Sutapa Sinha, Michael J Hansen, Carli M Stewart, Jennifer M Feigin, Claudia Manriquez Roman, Kendall J Schick, Ismail Can, Erin E Tapper, Paulina Horvei, Mohamad M Adada, Evandro D Bezerra, Lionel Aurelien A Kankeu Fonkoua, Michael W Ruff, Cynthia L Forsman, Wendy K Nevala, Justin C Boysen, Renee C Tschumper, Cory L Grand, Kamesh R Kuchimanchi, Lars Mouritsen, Jason M Foulks, Steven L Warner, Timothy G Call, Sameer A Parikh, Wei Ding, Neil E Kay, Saad Sirop Kenderian
AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells. Cancer immunology research (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology 99 (2) (2023)
R Leo Sakemura, Michelle J Cox, Mehrdad Hefazi, Elizabeth L Siegler, Saad Sirop Kenderian
Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies. Leukemia & lymphoma 62 (9) (2021)
Talha Badar, Aniko Szabo, Shira Dinner, Michaela Liedtke, Madelyn Burkart, Rory M Shallis, Ilana R Yurkiewicz, Eric Kuo, Muhammad Ali Khan, Suresh Balasubramanian, Jay Yang, Mehrdad Hefazi, Nikolai A Podoltsev, Anand Ashwin Patel, Emily Curran, Amy Wang, Shukaib Arslan, Ibrahim Aldoss, Caitlin Siebenaller, Ryan J Mattison, Mark R Litzow, Martha Wadleigh, Anjali S Advani, Ehab Atallah
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer 127 (7) (2020)